OncoMatch/Clinical Trials/NCT06204835
ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
Is NCT06204835 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies RD-Cy7 fluorophore for hepatocellular carcinoma.
Treatment: RD-Cy7 fluorophore — In this study, the investigators will detect hepatocellular carcinoma lesions using fluoescence imaging with ITGA6 targeting probes during tumor resection surgery. The aim is to evaluate wether intraoperative fluorescence imaging targeting ITGA6 can help to improve the detction effect of hepatocellular carcinoma, and finally help the accurate surgical resection. The main purposes of this study include: 1. To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the ITGA6 targeting probe. 2. To validate the safety and effectiveness of the proposed ITGA6 targeting probes for clinical application.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: ITGA6 highly expressed (high)
ITGA6 was validated highly expressed preoperatively.
Demographics
Lab requirements
Liver function
child-pugh a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06204835 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ITGA6?
Yes, ITGA6 highly expressed is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages